Leap Therapeutics jumps into growing Claudin18.2 field by buying Flame Biosciences

Kyle LaHucik

Senior Reporter

Flame Biosciences gave up on its IL-1ß inhibitor last fall after Novartis’ asset in the class failed multiple studies. To save itself, the biotech is selling to Leap Therapeutics.

Not in the foreground of the picture? The IL-1ß inhibitor, known as FL-101. Instead, Leap’s buyout focuses on anti-Claudin18.2 antibody FL-301 and two preclinical antibodies, including an anti-Claudin18.2/CD137 bispecific and anti-GDF15 monoclonal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Leap Therapeutics jumps into growing Claudin18.2 field by buying Flame Biosciences

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Sanofi restructures US commercial vaccines sales force

Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment

Leap Ther­a­peu­tics jumps in­to grow­ing Claudin18.2 field by buy­ing Flame Bio­sciences

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

Sanofi re­struc­tures US com­mer­cial vac­cines sales force

His­to­gen files for bank­rupt­cy; Barinthus Bio shares Ph1b/2 da­ta for HPV treat­ment

Leap Therapeutics jumps into growing Claudin18.2 field by buying Flame Biosciences

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Sanofi restructures US commercial vaccines sales force

Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment